In vitro evaluation of anticancer drugs using cancer cells has long been performed for the development of novel drugs and the selection of effective drugs for different patients. Recent studies have suggested that tumor stromal cells affect the drug sensitivity of cancer cells; however, most conventional culture systems for drug evaluation lack stromal cells. In this study, we fabricated a multicomponent coculture system that takes account of cancer–stroma interactions for drug evaluation. In this system, small-cell and nonsmall-cell lung cancer cells embedded in collagen gel were cocultured with two types of stromal cells, including stromal fibroblasts and proinflammatory cytokine-secreting monocytes, thus recreating the in vivo cancer microenvironment. Cancer drug sensitivity was significantly altered by the presence of stromal cells. Fibroblasts induced resistance of cancer cells to anticancer drugs. Monocytes induced the upregulation of thymidine phosphorylase in cancer cells, promoting the conversion of an anticancer prodrug to a cytotoxic drug, and consequently enhanced the sensitivity of cancer cells to the anticancer prodrug. These results clearly show the importance of incorporating stromal cells into culture systems for drug evaluation. Our system will help to improve the accuracy of in vitro drug evaluation and provide useful information for the in vitro recreation of cancer microenvironments.
Get full access to this article
View all access options for this article.
References
1.
KobayashiH.Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness. Recent Results Cancer Res, 161, 48, 2003.
2.
HorningJ.L., SahooS.K., VijayaraghavaluS., DimitrijevicS., VasirJ.K., JainT.K., PandaA.K., and LabhasetwarV.3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm, 5, 849, 2008.
3.
KievitF.M., FlorczykS.J., LeungM.C., VeisehO., ParkJ.O., DisisM.L., and ZhangM.Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. Biomaterials, 31, 5903, 2010.
4.
TalukdarS., MandalM., HutmacherD.W., RussellP.J., SoekmadjiC., and KunduS.C.Engineered silk fibroin protein 3D matrices for in vitro tumor model. Biomaterials, 32, 2149, 2011.
5.
AryaN., SardanaV., SaxenaM., RangarajanA., and KattiD.S.Recapitulating tumour microenvironment in chitosan–gelatin three-dimensional scaffolds: an improved in vitro tumour model. J R Soc Interface, 9, 3288, 2012.
6.
TalukdarS., and KunduS.C.A non-mulberry silk fibroin protein based 3D in vitro tumor model for evaluation of anticancer drug activity. Adv Funct Mater, 22, 4778, 2012.
7.
HartmanO., ZhangC., AdamsE.L., Farach-CarsonM.C., PetrelliN.J., ChaseB.D., and RaboltJ.F.Microfabricated electrospun collagen membranes for 3-D cancer models and drug screening applications. Biomacromolecules, 10, 2019, 2009.
8.
KimJ.B.Three-dimensional tissue culture models in cancer biology. Semin Cancer Biol, 15, 365, 2005.
9.
ShinC.S., KwakB., HanB., and ParkK.Development of an in vitro 3D tumor model to study therapeutic efficiency of an anticancer drug. Mol Pharm, 10, 2167, 2013.
10.
BremnesR.M., DønnemT., Al-SaadS., Al-ShibliK., AndersenS., SireraR., CampsC., MarinezI., and BusundL.T.The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol, 6, 209, 2011.
11.
van KempenL.C., RheeJ.S., DehneK., LeeJ., EdwardsD.R., and CoussensL.M.Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation, 70, 610, 2002.
12.
PietrasK., and OstmanA.Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res, 316, 1324, 2010.
13.
WangW., LiQ., YamadaT., MatsumotoK., MatsumotoI., OdaM., WatanabeG., KayanoY., NishiokaY., SoneS., and YanoS.Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res, 15, 6630, 2009.
14.
BartlingB., HofmannH.S., SilberR.E., and SimmA.Differential impact of fibroblasts on the efficient cell death of lung cancer cells induced by paclitaxel and cisplatin. Cancer Biol Ther, 7, 1250, 2008.
15.
MüerkösterS., WegehenkelK., ArltA., WittM., SiposB., KruseM.L., SebensT., KlöppelG., KalthoffH., FölschU.R., and SchäferH.Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res, 64, 1331, 2004.
MaH., LiuT., QinJ., and LinB.Characterization of the interaction between fibroblasts and tumor cells on a microfluidic co-culture device. Electrophoresis, 31, 1599, 2010.
18.
DickinsonL.E., LütgebaucksC., LewisD.M., and GerechtS.Patterning microscale extracellular matrices to study endothelial and cancer cell interactions in vitro. Lab Chip, 12, 4244, 2012.
19.
XuZ., GaoY., HaoY., LiE., WangY., ZhangJ., WangW., GaoZ., and WangQ.Application of a microfluidic chip-based 3D co-culture to test drug sensitivity for individualized treatment of lung cancer. Biomaterials, 34, 4109, 2013.
20.
YipD., and ChoC.H.A multicellular 3D heterospheroid model of liver tumor and stromal cells in collagen gel for anti-cancer drug testing. Biochem Biophys Res Commun, 433, 327, 2013.
21.
MekataE., MurataS., SonodaH., ShimizuT., UmedaT., ShiomiH., NakaS., YamamotoH., AbeH., EdamatsuT., FujiedaA., FujiokaM., WadaT., and TaniT.Protein-bound polysaccharide-K augments the anticancer effect of fluoropyrimidine derivatives possibly by lowering dihydropyrimidine dehydrogenase expression in gastrointestinal cancers. Oncol Rep, 30, 2845, 2013.
22.
PoppenborgH., KnüpferM.M., GallaH.J., and WolffJ.E.In vitro modulation of cisplatin resistance by cytokines. Cytokine, 11, 689, 1999.
23.
MiwaM., KojimaT., and NaruseT.Serum factors attenuating the anti-tumor activity of 5-fluorouracil. Cancer Biother Radiopharm, 16, 317, 2001.
24.
DevesaS.S., BrayF., VizcainoA.P., and ParkinD.M.International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer, 117, 294, 2005.
25.
JemalA., SiegelR., XuJ., and WardE.Cancer statistics, 2010. CA. Cancer J Clin, 60, 277, 2010.
26.
SandlerA.B., and BuzaidA.C.Lung cancer: a review of current therapeutic modalities. Lung, 170, 249, 1992.
27.
BartlingB., DemlingN., SilberR.E., and SimmA.Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products. Am J Respir Cell Mol Biol, 34, 83, 2006.
28.
CekanovaM., MasiT., PlummerH.K., 3rd, MajidiM., FedorockoP., and SchullerH.M.Pulmonary fibroblasts stimulate the proliferation of cell lines from human lung adenocarcinomas. Anticancer Drugs, 17, 771, 2006.
29.
MickeP., and OstmanA.Tumour–stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy?. Lung Cancer, 45, S163, 2004.
30.
SugimotoT., TakiguchiY., KurosuK., KasaharaY., TanabeN., TatsumiK., HiroshimaK., MinamihisamatsuM., MiyamotoT., and KuriyamaT.Growth factor-mediated interaction between tumor cells and stromal fibroblasts in an experimental model of human small-cell lung cancer. Oncol Rep, 14, 823, 2005.
31.
SpiroS.G., and SilvestriG.A.One hundred years of lung cancer. Am J Respir Crit Care Med, 172, 523, 2005.
32.
MiyakeH., HaraI., GohjiK., YoshimuraK., ArakawaS., and KamidonoS.Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett, 123, 121, 1998.
33.
SongS., WientjesM.G., GanY., and AuJ.L.Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A, 97, 8658, 2000.
34.
AlaviA.S., AcevedoL., MinW., and ChereshD.A.Chemoresistance of endothelial cells induced by basic fibroblast growth factor depends on Raf-1-mediated inhibition of the proapoptotic kinase, ASK1. Cancer Res, 67, 2766, 2007.
35.
MalgrangeB., DelréeP., RigoJ.M., BaronH., and MoonenG.Image analysis of neuritic regeneration by adult rat dorsal root ganglion neurons in culture: quantification of the neurotoxicity of anticancer agents and of its prevention by nerve growth factor or basic fibroblast growth factor but not brain-derived neurotrophic factor or neurotrophin-3. J Neurosci Methods, 53, 111, 1994.
36.
KönigA., MenzelT., LynenS., WrazelL., RosénA., Al-KatibA., RavecheE., and GabriloveJ.L.Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia, 11, 258, 1997.
37.
FenigE., LivnatT., Sharkon-PolakS., WassermanL., BeeryE., LillingG., YahalomJ., WiederR., and NordenbergJ.Basic fibroblast growth factor potentiates cisplatinum-induced cytotoxicity in MCF-7 human breast cancer cells. J Cancer Res Clin Oncol, 125, 556, 1999.
38.
WeissT., ShalitI., BlauH., WerberS., HalperinD., LevitovA., and FabianI.Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines. Antimicrob Agents Chemother, 48, 1974, 2004.
39.
SinghU., TabibianJ., VenugopalS.K., DevarajS., and JialalI.Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. Clin Chem, 51, 2252, 2005.
40.
HåversenL., OhlssonB.G., Hahn-ZoricM., HansonL.A., and Mattsby-BaltzerI.Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappaB. Cell Immunol, 220, 83, 2002.
41.
WhiteB., SchmidtM., MurphyC., LivingstoneW., O'TooleD., LawlerM., O'NeillL., KelleherD., SchwarzH.P., and SmithO.P.Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol, 110, 130, 2000.
42.
EdaH., FujimotoK., WatanabeS., UraM., HinoA., TanakaY., WadaK., and IshitsukaH.Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol, 32, 333, 1993.
43.
IshikawaT., UraM., YamamotoT., TanakaY., and IshitsukaH.Selective inhibition of spontaneous pulmonary metastasis of Lewis lung carcinoma by 5′-deoxy-5-fluorouridine. Int J Cancer, 61, 516, 1995.
44.
HaraguchiM., FurukawaT., SumizawaT., and AkiyamaS.Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res, 53, 5680, 1993.
45.
MiwaM., CookA., and IshitsukaH.Enzymatic cleavage of various fluorinated pyrimidine nucleosides to 5-fluorouracil and their antiproliferative activities in human and murine tumor cells. Chem Pharm Bull (Tokyo), 34, 4225, 1986.
46.
WangG., ReedE., and LiQ.Q.Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep, 12, 955, 2004.
47.
HorieM., FukuiH., NishioK., EndohS., KatoH., FujitaK., MiyauchiA., NakamuraA., ShichiriM., IshidaN., KinugasaS., MorimotoY., NikiE., YoshidaY., and IwahashiH.Evaluation of acute oxidative stress induced by NiO nanoparticles in vivo and in vitro. J Occup Health, 53, 64, 2011.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
